BrainsWay Announces Strategic Investment In Neurolief Ahead Of FDA Approval And Commercial Launch Of Proliv Rx For Major Depressive Disorder

Author: Benzinga Newsdesk | August 21, 2025 09:34am

 Neurolief, a pioneering brain stimulation company specializing in non-invasive neuromodulation therapies, today announced a strategic investment from BrainsWay Ltd. (NASDAQ & TASE: BWAY), a publicly-traded global leader in non-invasive neurostimulation treatments for mental health disorders. This investment marks a significant milestone as Neurolief awaits FDA approval and prepares for commercial launch of its Proliv™Rx, designed for the treatment of Major Depressive Disorder (MDD). The partnership reflects an exciting strategic alignment between the two companies, both of which are dedicated to expanding access to innovative, clinically validated and non-invasive mental health treatments.

Posted In: BWAY